Literature DB >> 23212106

Prospects for treatment of latent HIV.

K M Barton1, B D Burch, N Soriano-Sarabia, D M Margolis.   

Abstract

Recent advances in antiretroviral therapy (ART) have drastically improved the quality of life for people with HIV infection. However, owing to the persistence of latent HIV in the presence of therapy, patients must remain on therapy indefinitely. Currently, the solution to the HIV pandemic rests on the prevention of new infections and many decades of ART for the steadily expanding number of people infected worldwide. ART is costly, requires ongoing medical care, and can have side effects, thereby preventing its universal availability. Therefore, to escape the ironic burdens of therapy, efforts have begun to develop treatments for latent HIV infection. Current approaches propose either complete eradication of infection or induction of a state of stringent control over viral replication without ART. This review will discuss these strategies in detail and their potential for clinical development.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23212106      PMCID: PMC3942883          DOI: 10.1038/clpt.2012.202

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  68 in total

1.  Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice.

Authors:  Q Ma; D Jones; P R Borghesani; R A Segal; T Nagasawa; T Kishimoto; R T Bronson; T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

2.  Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat).

Authors:  Antonio Furlan; Valmen Monzani; Leonid L Reznikov; Flavio Leoni; Gianluca Fossati; Daniela Modena; Paolo Mascagni; Charles A Dinarello
Journal:  Mol Med       Date:  2011-02-22       Impact factor: 6.354

3.  RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma.

Authors:  David L DiGiusto; Amrita Krishnan; Lijing Li; Haitang Li; Shirley Li; Anitha Rao; Shu Mi; Priscilla Yam; Sherri Stinson; Michael Kalos; Joseph Alvarnas; Simon F Lacey; Jiing-Kuan Yee; Mingjie Li; Larry Couture; David Hsu; Stephen J Forman; John J Rossi; John A Zaia
Journal:  Sci Transl Med       Date:  2010-06-16       Impact factor: 17.956

4.  Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation.

Authors:  Sifei Xing; Cynthia K Bullen; Neeta S Shroff; Liang Shan; Hung-Chih Yang; Jordyn L Manucci; Shridhar Bhat; Hao Zhang; Joseph B Margolick; Thomas C Quinn; David M Margolis; Janet D Siliciano; Robert F Siliciano
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

5.  Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent.

Authors:  M Andreeff; R Stone; J Michaeli; C W Young; W P Tong; H Sogoloff; T Ervin; D Kufe; R A Rifkind; P A Marks
Journal:  Blood       Date:  1992-11-15       Impact factor: 22.113

6.  Host cell gene expression during human immunodeficiency virus type 1 latency and reactivation and effects of targeting genes that are differentially expressed in viral latency.

Authors:  Vyjayanthi Krishnan; Steven L Zeichner
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

7.  Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy.

Authors:  Stephen A Migueles; Kristin A Weeks; Eric Nou; Amy M Berkley; Julia E Rood; Christine M Osborne; Claire W Hallahan; Nancy A Cogliano-Shutta; Julia A Metcalf; Mary McLaughlin; Richard Kwan; JoAnn M Mican; Richard T Davey; Mark Connors
Journal:  J Virol       Date:  2009-09-02       Impact factor: 5.103

8.  Excision of HIV-1 proviral DNA by recombinant cell permeable tre-recombinase.

Authors:  Lakshmikanth Mariyanna; Poornima Priyadarshini; Helga Hofmann-Sieber; Marcel Krepstakies; Nicole Walz; Adam Grundhoff; Frank Buchholz; Eberhard Hildt; Joachim Hauber
Journal:  PLoS One       Date:  2012-02-13       Impact factor: 3.240

9.  CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection.

Authors:  Joseph Anderson; Ramesh Akkina
Journal:  Retrovirology       Date:  2005-08-18       Impact factor: 4.602

10.  HMBA releases P-TEFb from HEXIM1 and 7SK snRNA via PI3K/Akt and activates HIV transcription.

Authors:  Xavier Contreras; Matjaz Barboric; Tina Lenasi; B Matija Peterlin
Journal:  PLoS Pathog       Date:  2007-10-12       Impact factor: 6.823

View more
  38 in total

1.  Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies.

Authors:  Amanda M Crooks; Rosalie Bateson; Anna B Cope; Noelle P Dahl; Morgan K Griggs; JoAnn D Kuruc; Cynthia L Gay; Joseph J Eron; David M Margolis; Ronald J Bosch; Nancie M Archin
Journal:  J Infect Dis       Date:  2015-04-15       Impact factor: 5.226

2.  How Might We Cure HIV?

Authors:  David M Margolis
Journal:  Curr Infect Dis Rep       Date:  2014-03       Impact factor: 3.725

3.  Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir.

Authors:  Julia A Sung; Sharon Lam; Carolina Garrido; Nancie Archin; Cliona M Rooney; Catherine M Bollard; David M Margolis
Journal:  J Infect Dis       Date:  2015-01-13       Impact factor: 5.226

4.  Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy-treated macaques.

Authors:  Philip J Santangelo; Kenneth A Rogers; Chiara Zurla; Emmeline L Blanchard; Sanjeev Gumber; Karen Strait; Fawn Connor-Stroud; David M Schuster; Praveen K Amancha; Jung Joo Hong; Siddappa N Byrareddy; James A Hoxie; Brani Vidakovic; Aftab A Ansari; Eric Hunter; Francois Villinger
Journal:  Nat Methods       Date:  2015-03-09       Impact factor: 28.547

Review 5.  Eradicating HIV-1 infection: seeking to clear a persistent pathogen.

Authors:  Nancie M Archin; Julia Marsh Sung; Carolina Garrido; Natalia Soriano-Sarabia; David M Margolis
Journal:  Nat Rev Microbiol       Date:  2014-11       Impact factor: 60.633

6.  Designed transcription activator-like effector proteins efficiently induced the expression of latent HIV-1 in latently infected cells.

Authors:  Xiaohui Wang; Pengfei Wang; Zheng Fu; Haiyan Ji; Xiying Qu; Hanxian Zeng; Xiaoli Zhu; Junxiao Deng; Panpan Lu; Shijun Zha; Zhishuo Song; Huanzhang Zhu
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

7.  FACT Proteins, SUPT16H and SSRP1, Are Transcriptional Suppressors of HIV-1 and HTLV-1 That Facilitate Viral Latency.

Authors:  Huachao Huang; Netty Santoso; Derek Power; Sydney Simpson; Michael Dieringer; Hongyu Miao; Katerina Gurova; Chou-Zen Giam; Stephen J Elledge; Jian Zhu
Journal:  J Biol Chem       Date:  2015-09-16       Impact factor: 5.157

8.  Dilazep synergistically reactivates latent HIV-1 in latently infected cells.

Authors:  Hanxian Zeng; Sijie Liu; Pengfei Wang; Xiying Qu; Haiyan Ji; Xiaohui Wang; Xiaoli Zhu; Zhishuo Song; Xinyi Yang; Zhongjun Ma; Huanzhang Zhu
Journal:  Mol Biol Rep       Date:  2014-08-05       Impact factor: 2.316

Review 9.  Emerging strategies to deplete the HIV reservoir.

Authors:  Nancie M Archin; David M Margolis
Journal:  Curr Opin Infect Dis       Date:  2014-02       Impact factor: 4.915

Review 10.  Latency reversal and viral clearance to cure HIV-1.

Authors:  David M Margolis; J Victor Garcia; Daria J Hazuda; Barton F Haynes
Journal:  Science       Date:  2016-07-22       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.